CSI Market
Sign In | Register

Novabridge Biosciences (NBP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NBP Annual Cash Flow →
Observing cash flow movements over recent quarters helps explain how Novabridge Biosciences adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		0 0 0 (Dec 31 2024)
Operating Activities
Income-46.27
Depreciation & amortization0.07
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment-0.02
Share-based Compensation0.84
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Interest Expense Debt-
Assets Fair Value Adjustment-
Income From Other Financial Assets-
Loss From Conversion Of Notes-
Loss From Conversion Of Onshore Convertible Loans-
Loss From Issuance Of Notes-
Amortization Of Right Of Use Assets And Interest Of Lease Liabilities-
Fair Value Change Of Short Term Investments-
Increase Decrease In Contract With Customer Asset-
Increase Decrease In Contract With Customer Liability-
Increase Decrease Advance From Customers-
Fair Value Adjustments And Extinguishments Of Put Right Liabilities-
Settlement Of T J Biopharma Repurchase Obligations-
Amortization Of Right Of Use Assets-
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest-
Increase Decrease In Operating Lease Liability-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities2.55
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.10
Other Working Capital0.51
Other Noncash Income (Expense)0.00
Other net-5.93
Payments for (Proceeds from) Other Operating Activities18.44
Discontinued operations0.00
Net Cash flow from Operating Activities-2.91
Investing Activities
Capital Expenditures0.01
Sale of Capital Items0.05
Payments to Acquire Short-term Investments49.96
Short-term Investments Acq.0.00
Real Estate Investments0.00
Cash Received On Income From Short Term Investments-
Cash Received On Income From Other Financial Assets-
Capital Injection In An Affiliate-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale, Maturity and Collection of Investments21.85
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities14.81
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.20
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-80.85
Proceeds From Issuance Of Convertible Loans-
Proceeds From Cash Received From Collection Of Prepayment For Stock Repurchase Program-
Payments Of The Issuance Cost In Relation To Private Placement-
Payments Of Cost In Relation To Planned Dual Listing-
Prepayments For Repurchase Of Equity-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Operating Lease Payments-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Payables For Purchase Of Property Equipment And Software-
Debt Securities Available For Sale Unrealized Gain Loss-
Proceeeds From Underwritten Offering Net-
Potential Payments Of Deferred Offering Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities8.14
Effect of exchange rate on cash flow0.28
Discontinued operations0.00
Free Cash Flow-2.85
Total Cash Flow20.08
4 historic quarters locked

Sign in to unlock the full Novabridge Biosciences cash flow history.

Sign In Create Free Account

About Novabridge Biosciences Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

  • Form: 20-F (Period: 20251231)
  • Filed with the SEC: April 7, 2026
  • Source: nbp-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001778016-26-000002

Figures are derived from filed reports and may be restated. Historical data is subject to revision.